Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer

Human Pathology

Volumn 27, Issue 9, 1996, Pages 922-926

  Têtu, Bernard ^a,b   Allard, Pierre ^a   Fradet, Yves ^a   Roberge, Nancy ^a   Bernard, Pascale ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

bladder cancer; DNA ploidy; flow cytometry; S phase fraction; transitional cell carcinoma

Indexed keywords

CELL NUCLEUS DNA;

ANEUPLOIDY; ARTICLE; BLADDER CANCER; CELL CYCLE S PHASE; CLINICAL TRIAL; DIPLOIDY; DNA CONTENT; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PLOIDY; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE;

EID: 0029831343     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90219-1     Document Type: Article

References (35)

1. Ro JY, Staerkel GA, Ayala AG: Cytologic and histologic features of superficial bladder Cancer. Urol Clin North Am 19:435-453, 1992
2. Kiemeney LALM, Witjes JA, Verbeek ALM, et al: The clinical epidemiology of superficial bladder cancer. Br J Cancer 67:806-812, 1993
3. Koss LG, Czerniak B, Herz F, et al: Flow cytometric measurements of DNA and other cell components in human tumors: A critical appraisal. HUM PATHOL 20:528-548, 1989
4. Norming U, Tribukait B, Nyman CR, et al: Prognostic significance of mucosal aneuploidy in stage Ta/T1 grade 3 carcinoma of the bladder. J Urol 148:1420-1427, 1992
5. Blomjous ECM, Schipper NW, Baak JPA, et al: The value of morphometry and DNA flow cytometry in addition to classic prognosticators in superficial urinary bladder carcinoma. Am J Clin Pathol 91:243-248, 1989
6. Saracino GA, Ditonno P, Disabato G, et al: Prediction of recurrence and progression in primary superficial bladder cancer with DNA flow cytometry. Eur Urol 21:26-30, 1992 (suppl 1P)
7. Miao T, Wang Z, Sang N, et al: Clinical significance of flow cytometric deoxyribonucleic acid measurements of deparaffinized specimens in bladder tumors. Eur Urol 21:98-102, 1992
8. Russo A, Bazan V, Campanella R, et al: Flow cytometric DNA analysis in prediction of intravesical recurrence from human bladder cancer. Int J Oncol 5:633-638, 1994
9. Lipponen PK, Nordling S, Eskelinen MJ, et al: Flow cytometry in comparison with mitotic index in predicting disease outcome in transitional-cell bladder cancer. Int J Cancer 53:42-47, 1993
10. Jacobsen AB, Berner A, Juul M, et al: DNA flow cytometry and neo-adjuvant chemotherapy/radiotherapy in operable muscle-invasive bladder carcinoma: A preliminary report. Eur Urol 22:316-322, 1992
11. Tachibana M, Deguchi N, Baba S, et al: Prognostic significance of bromodeoxyuridine high labeled bladder cancer measured by flow cytometry: Does flow cytometric determination predict the prognosis of patients with transitional cell carcinoma of the bladder. J Urol 149:739-743, 1993
12. Allard P, Fradet Y, Têtu B, et al: Tumor associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell bladder carcinoma. Clin Cancer Res 1:1195-1202, 1995
13. Jordan AM, Weingarten J, Murphy WM: Transitional cell neoplasms of the urinary bladder: Can biologic potential be predicted from histologic grading? Cancer 60:2766-2774, 1987
14. Hedley CW, Friedlander ML, Taylor IW, et al: Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31:1333-1335, 1983
15. Dressier LG, Bartow SA: DNA flow cytometry in solid tumors: Practical aspects and clinical applications. Semin Diagn Pathol 6:55-82, 1989
16. Shankey TV, Rabinovitch PS, Bagwell B, et al: Guidelines for implementation of clinical DNA cytometry. Cytometry 14:472-477, 1993
17. Hsu S-M, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-580, 1981
18. Têtu B, Fradet Y, Allard P, et al: Prevalence and clinical significance of HER-2/neu, p53 and Rb expression in primary superficial bladder cancer. J Urol 155:1784-1788, 1996
19. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:453-481, 1958
20. Armitage P: Statistical methods in medical research. New York, NY, John Wiley & Sons 1991
21. Cox DR: Regression models and lifetables (with discussion). J R Stat Soc 34:187-220, 1972
22. Badalament RA, Fair WR, Whitmore WF Jr, et al: The relative value of cytometry and cytology in the management of bladder cancer: The Memorial Sloan-Kettering Cancer Center experience. Semin Urol 6:22-30, 1988
23. Têtu B, Katz RL, Kalter SP, et al: Acridine-orange flow cytometry of urinary bladder washings for the detection of transitional cell carcinoma of the bladder: The influence of prior local therapy. Cancer 60:1815-1822, 1987
24. Tribukait B: Flow cytometry in assessing the clinical aggressiveness of genitourinary neoplasms. World J Urol 5:108-122, 1987
25. Murphy WM, Chandler RW, Trafford RM: Flow cytometry of deparaffinized nuclei compared to histological grading for the pathological evaluation of transitional cell carcinomas. J Urol 135:694-697, 1986
26. deVere White RW, Deitch AD, West B, et al: The predictive value of flow cytometric information in the clinical management of stage O (Ta) bladder cancer. J Urol 139:279-282, 1988
27. Lipponen PK, Eskelinen MJ, Jauhiainen K, et al: Proliferation indices as independent prognostic factors in papillary Ta-T1 transitional cell bladder tumours. Br J Urol 72:451-457, 1993
28. Jacobsen A-B, Pettersen EO, Amellem O, et al: The prognostic significance of deoxyribonucleic acid flow cytometry in muscle invasive bladder carcinoma treated with preoperative irradiation and cystectomy. J Urol 147:34-37, 1992
29. Badalament RA, O'Toole RV, Keyhani-Rofagha S, et al: Flow cytometric analysis of primary and metastatic bladder cancer. J Urol 143:912-916, 1990
30. Wheeless LL, Badalament RA, deVere White RW, et al: Consensus review of the clinical utility of DNA cytometry in bladder cancer. Cytometry 14:478-481, 1993
31. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 85:53-59, 1993
32. Lipponen PK: Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 53:365-370, 1993
33. Sato K, Moriyama M, Mori S, et al: An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 70:2493-2498, 1992
34. Bush C, Price P, Norton J, et al. Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: Its potential clinical importance. Br J Cancer 64:357-360, 1991
35. Mulder AH, Van Hootegem JCSP, Sylvester R, et al: Prognostic factors in bladder carcinoma: Histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67). J Pathol 166:37-43, 1992